Search

everythinglearnresearchcommunity

for

Search:↓

Patients with a specific genetic variant have more severe alopecia areata and higher recurrence rates.

Monoclonal antibodies are often linked to alopecia areata cases.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.

AB+ blood group is more common in alopecia areata patients.

Higher leptin and lower vitamin D levels may contribute to male pattern baldness.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.

Arg1+ macrophages may play a role in causing alopecia areata.

Researchers found a new ABCD1 gene mutation linked to a rare brain and nerve disorder with unusual brain changes.

Angiopoietin-1 helps hair cells survive and grow, making it a potential treatment for hair loss.

Congenital atrichia with papular lesions causes permanent hair loss and skin bumps due to a gene mutation.

Targeting IL-15 may help treat Alopecia Areata.

An elderly man with skin amyloidosis and abnormal blood proteins was monitored without finding widespread disease after 18 months.

Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.

Lower Paraoxonase 1 levels in alopecia areata patients suggest antioxidant treatment might help.

Abatacept may help some people with alopecia areata regrow hair.

ATP6AP1‐CDG can cause hearing loss, hair loss, and protein issues, even in female carriers.

Vitamin D receptor gene changes don't affect alopecia areata risk.

Lower vitamin D levels are linked to higher CRP levels in people with a type of hair loss called alopecia areata.

ME1 and PPAR signaling may influence hair loss in androgenetic alopecia.

Certain gene variations increase the risk of alopecia areata in Koreans.

Adalimumab may cause severe hair loss in some patients.

CD8A and FOXD2-AS1 may be key for diagnosing and treating alopecia areata.

IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.

The C-allele and CC-genotype in the PTPN22 gene lower the risk of alopecia areata.

Osteopontin may play a role in alopecia areata, but its levels don't predict treatment success.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.